Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAL-083 with Radiation in Newly Diagnosed Unmethylated MGMT GBM
NCT03050736Phase 2Completed
- Sponsor
- Kintara Therapeutics
- Start
- Dec 2017
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dianhydrogalactitol in glioblastoma (GBM), sponsored by Kintara Therapeutics. Started Dec 2017; status: completed.
02
Drugs
dianhydrogalactitol
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03050736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03050736.